The Daily Biotech Pulse: Astrazeneca goes shopping, Tyme Technologies & Syros Pharma merger
The Daily Biotech Pulse: Astrazeneca goes shopping, Tyme Technologies & Syros Pharma merger
每日生物技术脉搏：阿斯利康去购物，泰姆科技和赛罗斯制药合并
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是过去24小时生物技术领域的热门发展综述：
Stocks In Focus
关注的股票
AstraZeneca Strengthens Its Hematological Cancer Pipeline With TeneoTwo Acquisition
阿斯利康通过收购TeneoTwo加强其血液癌症管道
AstraZeneca(AZN.US) has agreed to acquire TeneoTwo, Inc, including its Phase 1 clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.
阿斯利康(AZN.US)该公司已同意收购。TeneoTwo，Inc.，包括其临床1期CD19/CD3 T细胞激活剂TNB-486，目前正在对复发和难治性B细胞非霍奇金淋巴瘤进行评估。
Deal consideration includes an upfront payment of $100 million. AstraZeneca will make additional contingent R&D-related milestone payments of up to $805 million and additional contingent commercial-related milestone payments of up to $360 million to TeneoTwo's equity holders.
交易对价包括1亿美元的预付款。阿斯利康将向TeneoTwo的股东支付高达8.05亿美元的额外或有研发相关里程碑付款，以及高达3.6亿美元的额外或有商业相关里程碑付款。
TYME Technologies Shares Surge...
泰姆科技...
登录免费看全文
登录/注册